GNLX
Genelux Corporation
$3.11
+9.89%
2026-05-08
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Key Fundamentals
Forward P/E
-3.50
EPS (TTM)
$-0.86
ROE
-170.0%
Profit Margin
0.0%
Debt/Equity
14.60
Price/Book
9.40
Beta
0.50
Market Cap
$129.0M
Avg Volume (10D)
140K
Recent Breakout Signals
No recent breakout signals detected for GNLX.
Recent Price Range (60 Days)
60D High
$3.20
60D Low
$2.29
Avg Volume
181K
Latest Close
$3.11
Get breakout alerts for GNLX
Sign up for Breakout Scanner to receive daily notifications when GNLX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Genelux Corporation (GNLX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GNLX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GNLX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.